Pure Global
NCT06225492

DaxibotulinimtoxinA for Treatment of Platysmal Neck Bands

Use of DaxibotulinimtoxinA Injection for Platysma Bands of the Neck
Main Line Center for Laser Surgery·Phase 4·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Aging
Drug/Device/Intervention
DaxibotulinumtoxinA 15 units
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Main Line Center for Laser Surgery
Location
Ardmore, United States of America
Timeline & enrollment
Phase
Phase 4
Start date
Jan 01, 2024
End date
Jan 01, 2026
Enrollment
20 participants
Primary outcome

Effectiveness of DaxibotulinumtoxinA for platysmal neck bands measured on Platysmal Neck Banding Scale

Summary

This study seeks to evaluate the effectiveness and duration of action of DaxibotulinumtoxinA
 for neck rejuvenation through treatment of platysmal bands. This study will consist of one
 treatment visit with subjects being randomized to receiving 15 or 20 units of
 DaxibotulinumtoxinA per platysmal band. Subjects will return for 5 follow-up visits at 8, 12,
 16, 20, and 24 weeks for evaluation.

ICD-10 classifications
Alzheimer diseaseAgenesis and underdevelopment of noseAgenesis of lungAdult-onset Still diseaseChoroidal degeneration
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06225492
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06225492 through Pure Global AI's free database. This Phase 4 trial is sponsored by Main Line Center for Laser Surgery and is currently Recruiting. The study focuses on Aging. Target enrollment is 20 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.